Novartis AG Common Stock (NVS)

The company's second biggest product missed sales expectations. Shares look likely to undercut a buy zone.

Novartis posts solid Q2 results, raises 2025 earnings outlook, launches $10 billion share buyback, and announces CFO succession plan amid strong drug sales.

Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.

The stock slid to an intraday low of ₹6,545 on Monday following a gap-down open, as investors reacted to MSN’s legal win over Entresto.

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety concerns reported.

Novartis' Coartem Baby wins Swiss approval as the first malaria drug for newborns under 5 kg, offering safer dosing and easier administration.

The company said that it now expects rapid approval for the treatment in eight African countries, including Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Uganda, and Tanzania.

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery.

Giant cell arteritis (GCA) is the most common form of systemic vasculitis, a group of rare autoimmune diseases characterized by inflammation of blood vessels.

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial data.

The updated label applies to extended-release stimulants prescribed off-label to children under six, following data showing higher drug exposure and side effect rates in that age group.

FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.

Bill Meury previously led Karuna Therapeutics through a $14 billion sale to Bristol Myers Squibb and steered Anthos Therapeutics ahead of its acquisition by Novartis.

Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm.

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing.